The Lobbying Register, read carefully Epicycle

Returns

Every filed return on the register. Filter, then open any return on lobbying.ie to read it in full.

Clear all

Showing returns filed by Pfizer .

Filed returns
56
match these filters
Matching filed returns per period 0 1 2 3 5 May–Aug 2016: 3 filed returns Sep–Dec 2016: 3 filed returns Jan–Apr 2017: 2 filed returns May–Aug 2017: 2 filed returns Sep–Dec 2017: 4 filed returns Jan–Apr 2018: 1 filed returns Sep–Dec 2018: 1 filed returns May–Aug 2019: 1 filed returns May–Aug 2020: 2 filed returns Sep–Dec 2020: 2 filed returns Jan–Apr 2021: 2 filed returns May–Aug 2021: 2 filed returns Sep–Dec 2021: 3 filed returns Jan–Apr 2022: 2 filed returns May–Aug 2022: 3 filed returns Sep–Dec 2022: 1 filed returns Jan–Apr 2023: 1 filed returns May–Aug 2023: 1 filed returns Sep–Dec 2023: 3 filed returns Jan–Apr 2024: 1 filed returns May–Aug 2024: 2 filed returns Sep–Dec 2024: 2 filed returns Jan–Apr 2025: 3 filed returns May–Aug 2025: 2 filed returns Sep–Dec 2025: 2 filed returns Jan–Apr 2026: 3 filed returns May–Aug 2026: 2 filed returns 2017 2018 2021 2022 2023 2024 2025 2026
Filed returns per four-month period Click a column to list its returns.
PeriodRegistrantPolicy areaSubject, as filedOfficials namedLink
May–Aug 2026 Pfizer Health Discussion on the EU Biotech Act, access to medicines, innovation, and Ireland's life sciences policy environment, including opportunities to strengthen research, development, manufacturing, and the competitiveness of… (Public policy or programme) 3 On lobbying.ie
May–Aug 2026 Pfizer Health Expansion of the National Immunisation Programme to include RSV vaccination for older adults (Public policy or programme) 16 On lobbying.ie
Jan–Apr 2026 Pfizer Health Ireland’s National Life Sciences Strategy (Public policy or programme) 1 On lobbying.ie
Jan–Apr 2026 Pfizer Health Ireland's medicine reimbursement system and access to new medicine (Matters involving public funds) 2 On lobbying.ie
Jan–Apr 2026 Pfizer Health Expansion of the National Immunisation Programme to include RSV vaccination for older adults (Public policy or programme) 16 On lobbying.ie
Sep–Dec 2025 Pfizer Health Ireland's medicine reimbursement system and funding for access to new medicines and vaccines (Matters involving public funds) 4 On lobbying.ie
Sep–Dec 2025 Pfizer Health Expansion of the National Immunisation Programme to include RSV vaccination for older adults (Public policy or programme) 19 On lobbying.ie
May–Aug 2025 Pfizer Health Ireland's medicine reimbursement system and funding for access to new medicines and vaccines (Matters involving public funds) 9 On lobbying.ie
May–Aug 2025 Pfizer Health Expansion of the National Immunisation Programme to include RSV protection for infants and older adults (Public policy or programme) 9 On lobbying.ie
Jan–Apr 2025 Pfizer Health Treatment of Amyloidosis and ATTR-CM M (Public policy or programme) 1 On lobbying.ie
Jan–Apr 2025 Pfizer Health Expansion of the National Immunisation Programme to include RSV protection for infants and older adults (Public policy or programme) 6 On lobbying.ie
Jan–Apr 2025 Pfizer Health Ireland's medicine reimbursement system and funding for access to new medicines and vaccines (Matters involving public funds) 7 On lobbying.ie
Sep–Dec 2024 Pfizer Health Access to an antiviral medication for the treatment of COVID-19 (Matters involving public funds) 5 On lobbying.ie
Sep–Dec 2024 Pfizer Health Ireland's medicine reimbursement system and funding for access to new medicines and vaccines (Matters involving public funds) 15 On lobbying.ie
May–Aug 2024 Pfizer Health Digital Policy and the Life Science Industry (Public policy or programme) 1 On lobbying.ie
May–Aug 2024 Pfizer Health Ireland's medicine reimbursement system and access to new medicines and vaccines (Matters involving public funds) 1 On lobbying.ie
Jan–Apr 2024 Pfizer Health Ireland's medicine reimbursement system and access to new medicines and vaccines (Matters involving public funds) 14 On lobbying.ie
Sep–Dec 2023 Pfizer Health Exchange about the burden of sickle-cell disease in Europe and the Pfizer-supported call to action Shaping the Change for Sickle Cell Disease Patients in Europe and Beyond. (Public policy or programme) 1 On lobbying.ie
Sep–Dec 2023 Pfizer Health Migraine Summit (Public policy or programme) 1 On lobbying.ie
Sep–Dec 2023 Pfizer Health Ireland's medicine reimbursement system and Budget funding for new medicines (Matters involving public funds) 9 On lobbying.ie
May–Aug 2023 Pfizer Health Ireland's reimbursement system and funding for new medicines (Public policy or programme) 6 On lobbying.ie
Jan–Apr 2023 Pfizer Health Ireland's pricing and reimbursement system and funding for new medicines (Public policy or programme) 14 On lobbying.ie
Sep–Dec 2022 Pfizer Health Pfizer anti-viral COVID-19 treatment and COVID-19 cases (Public policy or programme) 1 On lobbying.ie
May–Aug 2022 Pfizer Health COVID-19 vaccination programme (Public policy or programme) 4 On lobbying.ie
May–Aug 2022 Pfizer Health Pfizer COVID-19 anti-viral treatment (Public policy or programme) 3 On lobbying.ie
May–Aug 2022 Pfizer Health PMB re orphan medicines, Health (Pricing and Supply of Medical Goods) (Amendment) Bill 2021 (Legislation) 1 On lobbying.ie
Jan–Apr 2022 Pfizer Health Update on Pfizer COVID 19 antiviral treatment and processes in ensuring availability of the treatment in Ireland (Matters involving public funds) 2 On lobbying.ie
Jan–Apr 2022 Pfizer Health PMB in relation to reimbursement of orphan medicines Health (Pricing and Supply of Medical Goods) (Amendment) Bill 2021 (Public policy or programme) 1 On lobbying.ie
Sep–Dec 2021 Pfizer Health Agreement on Pricing and Supply of Medicines 2021 - 2025 (Public policy or programme) 1 On lobbying.ie
Sep–Dec 2021 Pfizer Health COVID-19 vaccination programme (Public policy or programme) 5 On lobbying.ie
Sep–Dec 2021 Pfizer Health Pfizer has an investigational COVID-19 treatment, a protease inhibitor which subject to clinical trials and regulatory approvals could play a complementary role to vaccination in helping to manage COVID-19 (Matters involving public funds) 5 On lobbying.ie
May–Aug 2021 Pfizer Health Supply of Pfizer COVID-19 vaccine including Ireland volumes; expansion of manufacturing capacity to include Grange Castle site and Pfizer colleague vaccination programme (Public policy or programme) 8 On lobbying.ie
May–Aug 2021 Pfizer Health Outline Ireland's medicine reimbursement system and timelines compared with other countries (Public policy or programme) 1 On lobbying.ie
Jan–Apr 2021 Pfizer Health Highlight Ireland's slowness in reimbursing new medicines for Irish patients compared with other EU countries (Public policy or programme) 1 On lobbying.ie
Jan–Apr 2021 Pfizer Health Updates in relation to Pfizer COVID 19 vaccine including global production, Ireland volumes and company colleague vaccination programme (Matters involving public funds) 10 On lobbying.ie
Sep–Dec 2020 Pfizer Health Highlight Ireland's slowness in reimbursing innovative medicines compared to other European countries and outline factors contributing to this (Public policy or programme) 2 On lobbying.ie
Sep–Dec 2020 Pfizer Health Discussions in relation to Pfizer/BioNtech progress in development of a vaccine for COVID 19 (Public policy or programme) 3 On lobbying.ie
May–Aug 2020 Pfizer Health Highlighted discussions on extension of industry Supply Agreement and the importance of ensuring expenditure is efficently managed to ensure Irish patients can access innovative medicines; welcomed plans to progress the… (Public policy or programme) 28 On lobbying.ie
May–Aug 2020 Pfizer Health Provided information about Pfizer's research into a COVID-19 vaccine, meeting sought with MoH/DoH. (Public policy or programme) 29 On lobbying.ie
May–Aug 2019 Pfizer Health Ireland has become one of the slowest countries in Europe to reimburse innovative medicines for patients, now ranking 16th out of 26th according to EFPIA. (Public policy or programme) 2 On lobbying.ie
Sep–Dec 2018 Pfizer Health Ireland has become one of the slowest countries in Europe to reimburse innovative medicines for patients, now ranking 16th out of 26th according to EFPIA. (Public policy or programme) 1 On lobbying.ie
Jan–Apr 2018 Pfizer Health Pfizer is seeking reimbursement for a new treatment for metatastic breast cancer which is reimbursed in the majority of EU countries but not yet in Ireland. Ireland has become one of the slowest countries in Europe to… (Public policy or programme) 4 On lobbying.ie
Sep–Dec 2017 Pfizer Health Pfizer is seeking reimbursement for a new treatment for metatastic breast cancer which is reimbursed in the majority of EU countries but not yet in Ireland. Ireland has become one of the slowest countries in Europe to… (Public policy or programme) 5 On lobbying.ie
Sep–Dec 2017 Pfizer Health Science Foundation Ireland has a research centre, INNATE which has been approved in principle but requires funding. The infrastructure and focus intended by INNATE would help upskill scientists and help translate early… (Matters involving public funds) 1 On lobbying.ie
Sep–Dec 2017 Pfizer Health The Anti-Microbial Resistance Plan was due for publication in September 2017. The 3-year Plan covers the use of anti-microbial medicines in animal health and agriculture, and human health - taking a 'One Health'… (Public policy or programme) 1 On lobbying.ie
Sep–Dec 2017 Pfizer Health Pfizer launched 'MBC: A Call to Action' to highlight the unmet needs of metastatic breast cancer patients. MBC is an advanced form of breast cancer where early detection does not improve survival. Even if diagnosed with… (Public policy or programme) 14 On lobbying.ie
May–Aug 2017 Pfizer Health Ireland has now become one of the slowest countries in Europe to reimburse innovative medicines for patients. HTA assessment is prolonged and decisions after HTA are exceptionally slow with the majority of medicines… (Public policy or programme) 12 On lobbying.ie
May–Aug 2017 Pfizer Health Pfizer is seeking reimbursement for a new treatment for metastatic breast cancer. Metastatic breast cancer is an advanced form of breast cancer where early detection unfortunately does not improve survival. Even if… (Public policy or programme) 1 On lobbying.ie
Jan–Apr 2017 Pfizer Health A Supply Agreement was negotiated in 2016 between the pharmaceutical industry and the state which provides 785m in savings over four years, ensures Irish on patent medicine prices are in line with 14 other EU countries… (Public policy or programme) 7 On lobbying.ie
Jan–Apr 2017 Pfizer Health Pfizer is seeking reimbursement for a new treatment for metastatic breast cancer. Metastatic breast cancer is an advanced form of breast cancer where early detection unfortunately does not improve survival. Even if… (Matters involving public funds) 8 On lobbying.ie

Policy areas in these returns

Public policy areaFiled returnsShareRelative to the largest
Health 56 100.0%